New technologies reaching the clinic

Similar documents
Deep-Sequencing of HIV-1

Clinical utility of NGS for the detection of HIV and HCV resistance

Purification of viral nucleic acid from serum, plasma, cell-free biological fluids MACHEREY- NAGEL

Alexander Thielen 16th European Meeting on HIV & Hepatitis

Fifteen years of molecular EQA: progress and challenges

Technical Bulletin No. 162

Diagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)

HIV-1 resistance testing from proviral DNA

COMPARISON OF HIV DRUG-RESISTANT MUTANT DETECTION BY NGS WITH AND WITHOUT UNIQUE MOLECULAR IDENTIFIERS (UMI)

Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq

Diagnostic Methods of HBV and HDV infections

HBV. Next Generation Sequencing, data analysis and reporting. Presenter Leen-Jan van Doorn

Figure S1. Schematic presentation of genomic replication of idsiv after transfection and infection. After transfection of idsiv plasmid DNA into 293T

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere q HIV-1/2 Detect WHO reference number: PQDx

For purification of viral DNA and RNA from a wide range of sample materials

A complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis

Trends in molecular diagnostics

HIV and drug resistance Simon Collins UK-CAB 1 May 2009

AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits

Breast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS

Innovative diagnostics for HIV, HBV and HCV

Simple, rapid, and reliable RNA sequencing

Diagnosis of infectious diseases and confirmation of diagnosis. Molecular epidemiology of emerging/re-emerging pathogens

Standardization: Calibration of. International Standards, reference preparations and working standards. Micha Nübling, PEI

Introduction to the Impact of Resistance in Hepatitis C

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

ICAAC/IDSA DC, Oct. 26, 2008

Technical Bulletin No. 161

Chain of Infection Agent Mode of transmission Contact (direct, indirect, droplet spread) Airborne Common-vehicle spread Host

Viral RNA / DNA purification products from MACHEREY-NAGEL. MN guide for viral RNA / DNA purification Multiple solutions for many needs

Evaluation of MIA FORA NGS HLA test and software. Lisa Creary, PhD Department of Pathology Stanford Blood Center Research & Development Group

2/10/2016. Evaluation of MIA FORA NGS HLA test and software. Disclosure. NGS-HLA typing requirements for the Stanford Blood Center

NRL EQAS for NAT: Assessing the variability and performance of molecular assays for clinical pathogens

NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation

Monitoring for Drug Resistance by Genotyping. Urvi M Parikh, PhD MTN Virology Core Lab

To test the possible source of the HBV infection outside the study family, we searched the Genbank

Implementation of BRCA Oncomine panel for germline and somatic variant analysis

Best practice DNA prep for SMRT. Olga Vinnere Pettersson, PhD Project coordinator NGI-Sweden / SciLifeLab (UU)

Human diagnostics. Better be Sure: Quantify HDV & HBV viral load. RoboGene product family

MOLECULAR DIAGNOSTIC PANELS and REAGENT KITS for NUCLEIC ACID EXTRACTION and RT-PCR of INFECTIOUS DISEASES and GENOMICS. Sep 2018

Advance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library

HEV Assay Development Update

ExiPrep TM Dx Fully Automated Nucleic Acid Extraction

P. Tang ( 鄧致剛 ); PJ Huang ( 黄栢榕 ) g( ); g ( ) Bioinformatics Center, Chang Gung University.

C-CREST study, Part A: GZR + EBR or MK MK-3682 for genotypes 1, 2 and 3 - Phase II

Performance Characteristics BRCA MASTR Plus Dx

Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E,

HIV-1 Genemer Detection Kit Ready to Use Amplification Kit for HIV-1 Specific DNA Fragment Analysis

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients

Improving PI drug resistance scores. Jens Verheyen, MD Institute of Virology University Duisburg-Essen

The use of QCMD proficiency testing panels in clinical virology.

Circulating Cell-Free DNA Pre-analytics: Importance of ccfdna Stabilization and Extraction for Liquid Biopsy Applications

MENU PRODUCT MOLECULAR. International Product Listing. Simplexa Molecular Kits Integrated Cycler Molecular Reagents and Primer Pairs

HIV DNA Genotyping by UDS compared with cumulative HIV RNA Genotypes in Pretreated Patients

DETECTION OF LOW FREQUENCY CXCR4-USING HIV-1 WITH ULTRA-DEEP PYROSEQUENCING. John Archer. Faculty of Life Sciences University of Manchester

Hepatitis C Virus resistance screening and phenotypic NS3-PI-Resistance characterization. Arevir Meeting, 08./09.05.

DNA-seq Bioinformatics Analysis: Copy Number Variation

Multiplex target enrichment using DNA indexing for ultra-high throughput variant detection

Hepatitis B Virus Genemer

PRODUCT# PRODUCT NAME VOLUME

Routine NAT-screening for West Nile Virus Infections in Germany: Being prepared

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2011 Formula Grant

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ

Resistance Workshop. 3rd European HIV Drug

Introduction to Systems Biology of Cancer Lecture 2

RNA-seq Introduction

The Sequencing Continuum for Clinical Research: From Sanger to Next Gen Webinar 12 March 2014

QIAsymphony DSP Circulating DNA Kit

About HPV. Human papillomavirus (HPV) is a group of viruses that are extremely common worldwide. Theree are more than 100 types of HPV, of which at

Diversity and Tropism of HIV-1 Plasma Rebound Virus after Treatment Discontinuation

on October 4, 2018 by guest

Detection of aneuploidy in a single cell using the Ion ReproSeq PGS View Kit

Analysis of the genetic diversity of influenza A viruses using next-generation DNA sequencing

Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication

ICVH 2016 Oral Presentation: 28

ON O C N O C H O E H M E A M T A O T L O O L G O Y

QUALITY CONTROL for MOLECULAR DIAGNOSTICS Quality issues highlighted through international external quality assessment

Laboratory diagnostics CH/HIV/0052/17/10/2017

About the LIAISON MDX

HIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital

Analysis of HIV-1 Resistance Mutations from various Compartments of the Peripheral Blood in Patients with Low-Level Viremia

Investigating rare diseases with Agilent NGS solutions

QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing

Mutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research

Identification of hepatitis B virus DNA reverse transcriptase variants associated with partial response to entecavir

Use of Viral Load Testing in Managing CMV Infections in SOTR

AVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB

NAT / BLOOD SCREENING - PRODUCT RANGE

Case Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.

PRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES

Deep Sequencing Detects V3 loop Forms Present in Functional X4 Viruses Growing in MT 2 assays

Whole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy

NEXT GENERATION SEQUENCING OPENS NEW VIEWS ON VIRUS EVOLUTION AND EPIDEMIOLOGY. 16th International WAVLD symposium, 10th OIE Seminar

Accel-Amplicon Panels

Simple Solutions for Patient Monitoring. Maximum Flexibility 2 Configuration: 8 to 1000 viral load tests/day 2 Sample: Plasma/DBS

Virus Genetic Diversity

How to Standardise and Assemble Raw Data into Sequences: What Does it Mean for a Laboratory to Use Such Technologies?"

PG-Seq NGS Kit for Preimplantation Genetic Screening

Transcription:

New technologies reaching the clinic Martin Däumer May 31, 2018

Deep-sequencing Standard Sanger-sequencing...PQIYMDDHTRE... Ultra-deep-sequencing...PQIYMDDHTRE......PQIYMDDHTRE......PQIYVDDHTRE......PQIYMDDHTRE......PQIYMDDHTRE......PQIYMDDHTRE...

Developments in high-throughput sequencing

The players

Ion Torrent PGM (Personal Genome Machine) The chip is the machine

Ion Torrent workflow

Specifications

Vela Next Generation Sequencing NGS automation for the IVD routine laboratory Sentosa SQ HCV/HIV Genotyping Assay Sentosa Link Sample ID Download Samples 4 Validated Sample Materials; 2 Extraction Kits Sentosa SX101 Multi-purpose: Lysis, Extraction, Library Prep; Open-channel Sentosa ST401 Template Prep Sentosa SQ301 IVD Sequencing, Open-channel Sentosa SQ Reporter Data QC Automated Reporting Sentosa Link Result Upload Key Features CE-IVD Ready to use in 2 weeks from installation IT Connectivity Sample Tracking Control System Automation Ready to use Reagents Actionable Design Data Analysis Data Reporting

Sentosa SQ Virology Panels HCV and HIV Panel Specifications Parameters HCV HIV Regualtory Status CE-IVD CE-IVD Target Genes NS3, NS5A, NS5B Protease, Reverse Transcriptase, Integrase Genotyping capabilities Median Coverage/ Sample 1a, 1b, 2, 3, 4, 5, 6 (Analysis of all clinically relevant RAV s included) 200x for genotyping 500x for variants calling HIV-1 group M (subtypes AG, B, C, D, AE, F, G, CRF02, CRF03, A and recombinant A) 1,000x for genotyping and variant calling Sample Input Plasma (EDTA / CPD / ACD) and Serum Plasma (EDTA / CPD / ACD) Sample Throughput 15 patient samples and 1 system control 15 patient samples and 1 system control Analytical Sensitivity (Limit of detection) Analytical Specificity 1,000 HCV IU/mL for Genotypes 1a, 1b, 2, 3 and 4 2,000 HCV IU/mL for Genotypes 5, 6 No cross-reaction with Dengue virus, HAV, HBV, HIV, CMV, EBV, BKV, human genomic DNA 1,000 copies/ml No cross reactivity with Chlamydia trachomatis, Staphylococcus aureus, Mycobacterium smegmatis, HCV, Neisseria meningitidis, HHV6, BKV, EBV, Hep A, HBV CMV VZV HSV1 and HSV2

Sentosa SQ Workflow 15 clinical samples per run, 4 runs (60 samples) per week Monday Tuesday Wednesday Thursday Friday AM PM AM PM AM PM AM PM AM PM 1 SX101 ST401 SQ301 2 SX101 ST401 SQ301 3 SX101 ST401 SQ301 4 SX101 ST401 SQ301 Costs per sample (when running 15 samples): 110,-

Illumina platforms

MiSeq Personal Sequencing System Cluster generation and Sequencing-by-Synthesis

Library preparation using Nextera TM XT tagmentation Easy library preparation Fast - less than 15 minutes hands-on time Only 1ng DNA per sample needed 384 indices available Normalization step included

Library Normalization

Third generation sequencing

MinION Nanopore technology output: up to 21Gb (1D at 400 bps in 48 hours) read length: dependent on fragment size (longest reported read: 892 kb [1D]) Starter kit: $1.000 (1X minion, reagents for two runs)

Oxford Nanopore s technology

MinION Nanopore technology HIV-1 pol amplicon, 1.35kb

Oxford Nanopore s error rate

Rolling Circle Amplification random priming isothermal amplification by phi29 polymerase

RCA Approach: Final product copy 1 copy 2 copy n 80-100 kb

RCA Approach: Analysis copy 1 copy 2 copy n 80-100 kb Individual copies are detected in the sequenced reads and aligned against each other copy 1 x x copy 2 x x x... copy n x x x A consensus sequence is generated consensus

Results Basecalling errors at different sensitivity cut-offs:

Outlook: Direct RNA sequencing with ONT

Drug resistance testing (HIV) using Illumina s MiSeq

Experimental setup HIV genome PRRT IN ENV whole genome

Fragmentation

Automated Nextera XT library preparation

putting things together mapping PRRT IN ENV Reference sequences

Coverage ~10K to 20K ~10K to 20K PR/RT ENV ~7500 full V3 loops

Validation isolation NGS Sanger pooling rt-pcr/ nested pcr fragmentation & indexing sequencing 400 samples (PR/RT) sequencing analysis analysis comparison

PR/RT # resistance mutations found 236 230 239 252 275 324 499

Viral load cop/ml How much virus is relevant? 1% 1%

Number of mutations not detected by the respective sequencing approach (Sanger vs NGS and vice versa) at 2% and 10% NGS minority cutoff 0 0 n=30

Sanger vs NGS (same amplicon)

Workflow NGS RNA/DNA Total NA extraction Sanger Library preparation: fragmentation & indexing Sequencing reaction analysis PCR errors (Sequencing Errors) rt-pcr/ nested pcr RNA vs. DNA: viable vs non-viable RT/PCR errors, recombination Potential error sources editing Taq-cycle reaction, sequencing analysis

Deviations from the main variant (amino acid; in %) HIV-1 protease (clone) RT-PCR/nested PCR 1% H: SuperScript III One-Step RT-PCR System with Platinum Taq High Fidelity /Platinum Taq High Fidelity (Invitrogen/Thermo) QH: QIAGEN OneStep Ahead RT-PCR Kit/Platinum Taq High Fidelity QQ: QIAGEN OneStep Ahead RT-PCR Kit/QIAGEN HotStarTaq polymerase Q: QIAGEN OneStep RT-PCR Kit/QIAGEN HotStarTaq polymerase

Case report: T., T.-L. *1974 TDF/FTC/RPV Resistance tests, retrospective

Case report: T., T.-L. *1974 Date Mutation (%) TDF FTC RPV 05/2014 E138K (100%) 07/2014 E138K (100%) Y115F (5,6%) M184V (100%) V108I (100%) K219R (0,4%) 10/2014 K70E (1,8%) E138K (100%) Y115F (100%) V179L (1,6%) M184V (100%) V108I (100%) K219R (2,8%) 02/2015 K70E (100%) E138R (100%) Y115F (100%) V179L (100%) M184V (100%) V108I (100%) K219R (82%)

The deeptypehiv report generator Muts >10% Muts >2%<10% Patient identification and therapy data Scored mutations per drug Information on coverage Detailed information mut and wt frequency Data modules

The deeptypehiv report generator Use tick boxes for visualization of resistance situation: Susceptible Limited susceptibility Intermediate Resistant

The deeptypehiv report generator Preconfigured report components available

The deeptypehiv report generator, integrated HIV-GRADE interpretation

The deeptypehiv report

The deeptypehiv report

Cost per sample calculation Illumina MiSeq (2x250) (reagents only) 25 samples per week PRRT plus Integrase plus env V3 : 3.400 nts Coverage: 20.000 X sum: 1,7 Gb, spare capacity: 6-7 Gb (2x250nts) Sample and library preparation: 39,-/sample* Sequencing: 53,-/sample* total 92,-/sample (incl. of VAT) Bioinformatician not included ( There are some things money can t buy... for the rest there s Mastercard ) *based on Illumina s list prices in Germany 2017

Cost per raw Megabase

Acknowledgments Bettina Welter Kirsten Becker Anna Memmer Nina Engel Anja Laux Alexander Thielen Bernhard Thiele